Sign In

Yangbing Zhao

M.D&Ph.D

Yangbing Zhao is a prominent figure in the field of cancer immunotherapy, with a major interest in T cell based gene and adoptive cell therapies. He has held key positions in various prestigious organizations.

Currently, Yangbing Zhao serves as the President & CSO at UTC Therapeutics Inc. He previously held the role of Director at the T Cell Engineering Lab (TCEL) and Adjunct Associate Professor at the University of Pennsylvania.

Prior to his current role, he was a Research Fellow at the Surgery Branch under NCI/NIH. Additionally, Yangbing Zhao has worked as a Research Associate at Duke University Medical Center and has experience as a Post-Doc and Visiting Scientist at The Weizmann Institute of Science.

Highlights

Sep 1 · aacr.org
Advances in Immunotherapy: Fine-tuning CAR T Cells

Related Questions

What are Yangbing Zhao's key contributions to cancer immunotherapy?
How did Yangbing Zhao's work at the University of Pennsylvania influence his career?
What is the significance of Yangbing Zhao's role at UTC Therapeutics Inc?
Can you provide more details about the CAR-T therapies Yangbing Zhao was involved in?
What are the main goals of UTC Therapeutics Inc. under Yangbing Zhao's leadership?
Yangbing Zhao
Yangbing Zhao, photo 1
Yangbing Zhao, photo 2
Add to my network

Location

Shanghai, China